|
1) Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002; 38 (Suppl 5): S28-36
|
|
|
|
2) Zoja C, Corna D, Rottoli D, et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 2006; 70: 97-103
|
|
|
|
|
3) Sadanaga A, Nakashima H, Masutani K, et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum. 2005; 52: 3987-96
|
|
|
|
|
|
4) Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2005; 16: 363-73
|
|
|
|
|
|
5) Gilbert RE, Kelly DJ, McKay T, et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 2001; 59: 1324-32
|
|
|
|
|
|
6) Iyoda M, Hudkins KL, Becker-Herman S, et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol. 2009; 20: 68-77
|
|
|
|
|
|
7) Iyoda M, Shibata T, Kawaguchi M, et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int. 2009; 75: 1060-70
|
|
|
|
|
|
8) Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A. 1974; 71: 1207- 10
|
|
|
|
|
|
9) Li X, Ponten A, Aase K, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000; 2: 302-9
|
|
|
|
|
|
10) LaRochelle WJ, Jeffers M, McDonald WF, et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol. 2001; 3: 517-21
|
|
|
|
|
|
11) Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008; 19: 12-23
|
|
|
|
|
|
12) Johnson RJ, Floege J, Couser WG, et al. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993; 4: 119-28
|
|
|
|
|
|
13) Iida H, Seifert R, Alpers CE, et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci U S A. 1991; 88: 6560-4
|
|
|
|
|
|
14) Floege J, Eng E, Young BA, et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest. 1993; 92: 2952-62
|
|
|
|
|
|
15) Tang WW, Ulich TR, Lacey DL, et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol. 1996; 148: 1169-80
|
|
|
|
|
|
16) Hudkins KL, Gilbertson DG, Carling M, et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol. 2004; 15: 286-98
|
|
|
|
|
|
17) Floege J, Ostendorf T, Janssen U, et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol. 1999; 154: 169-79
|
|
|
|
|
|
18) Ostendorf T, Kunter U, Grone HJ, et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001; 12: 909-18
|
|
|
|
|
|
19) Ostendorf T, van Roeyen CR, Peterson JD, et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2003; 14: 2237-47
|
|
|
|
|
|
20) Ostendorf T, Rong S, Boor P, et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2006; 17: 1054-62
|
|
|
|
|
|
21) Boor P, Konieczny A, Villa L, et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant. 2007; 22: 1323-31
|
|
|
|
|
|
22) Hawthorne T, Giot L, Blake L, et al. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008; 46: 236-44
|
|
|
|
|
|
23) Eitner F, Bucher E, van Roeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol. 2008; 19: 281-9
|
|
|
|
|
|
24) Shinkai Y, Cameron JS. Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit. Br J Exp Pathol. 1987; 68: 847-52
|
|
|
|
|
|
25) Nakagawa T, Sasahara M, Haneda M, et al. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol. 1999; 155: 1689-99
|
|
|
|
|
|
26) Hirai T, Masaki T, Kuratsune M, et al. PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin Exp Immunol. 2006; 144: 353-61
|
|
|
|
|
|
27) Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation. 2003; 75: 1147-53
|
|
|
|
|
|
28) Gu JJ, Zhang N, He YW, et al. Defective T cell development and function in the absence of Abelson kinases. J Immunol. 2007; 179: 7334- 43
|
|
|
|
|
|
29) Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004; 18: 1332-9
|
|
|
|
|
|
30) Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005; 105: 2473-9
|
|
|
|
|
|
31) Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004; 104: 1094-9
|
|
|
|
|
|
32) Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006; 116: 2633-42
|
|
|
|
|
|
33) Lam QL, Lo CK, Zheng BJ, et al. Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice. Int Immunol. 2007; 19: 267-76
|
|
|
|
|
34) Waskow C, Paul S, Haller C, et al. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity. 2002; 17: 277-88
|
|
|
|
|
|
35) Dewar AL, Domaschenz RM, Doherty KV, et al. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia. 2003; 17: 1713-21
|
|
|
|
|
|
36) Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105: 3127-32
|
|
|
|
|
|
37) Dewar AL, Doherty KV, Hughes TP, et al. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol. 2005; 83: 48-56
|
|
|
|
|
|
38) Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004; 114: 379-88
|
|
|
|
|
|
39) Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114: 1308-16
|
|
|
|
|
|
40) Wang S, Wilkes MC, Leof EB, et al. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005; 19: 1-11
|
|
|
|
|
|
41) Lellouche F, Mancebo J, Jolliet P, et al. A multicenter randomized trial of computer-driven protocolized weaning from mechanical ventilation. Am J Respir Crit Care Med. 2006; 174: 894-900
|
|
|
|
|
|
42) Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005; 201: 925-35
|
|
|
|
|